Moderna COVID-19 Vaccine to Enter Phase 3 Trials this Month

Coronavirus epidemic continues wreaking havoc worldwide. Now, US biotech firm Moderna is preparing for the final stage trial of the Coronavirus vaccine.
Image credit: NBC News
Image credit: NBC News

Coronavirus epidemic continues wreaking havoc worldwide. Now, US biotech firm Moderna is preparing for the final stage trial of the Coronavirus vaccine. According to the company, this trial can be started on July 27. It would conduct trials of the vaccine at 87 locations in the US. People involved in the trial will be given a dose of 100 micrograms of the potential vaccine on the first day, followed by a second dose 29 days later. The company can make a big announcement soon.

Moderna's Coronavirus vaccine was successful in first trials:

US company Moderna's Coronavirus vaccine was a complete success in its first trial. The study, published in the New England Journal of Medicine, says that the first test of this vaccine on 45 healthy people had very good results. Another good thing about Moderna's vaccine is that it did not have such a significant side effect, because of which the trial of vaccine should be stopped. This first test included 45 such people who were healthy and their age was between 18 and 55 years.

Trial will be done in the most corona affected areas:

The trial of this potential vaccine will be done in 30 other states of the country. More than half of the locations selected for vaccine trials are located in Texas, California, Florida, Georgia, Arizona, and North and South Carolina, the most affected by the coronavirus.

The US government has also funded half a million dollars to develop the vaccine. The company claimed first two-phase trials of this vaccine as successful. However, the data related to this has not been shared by the company.

Image credit: The Financial Express
Image credit: The Financial Express

Company's shares increased three times:

According to reports, the shares of Moderna Company have increased more than three times since February. Listed on the US stock market Nasdaq, the company's stock is valued at $ 74.57 on Tuesday.

Human trial of two vaccines started in India:

In India too, human trials of two vaccine candidates, India Biotech and Zydus Cadila have started. Dr. Balram Bhargava said that it is our moral responsibility to fast-track the indigenous vaccine and make it available to the common people at the earliest.

Like and Follow us on :

Related Stories

No stories found.
Since independence
www.sinceindependence.com